Episode Details
Back to Episodes
Pharmaceutical Executive Daily: Vinay Prasad Set to Leave CBER for Second Time
Published 2 months, 1 week ago
Description
In today’s Pharmaceutical Executive Daily, Vinay Prasad exits the FDA’s Center for Biologics Evaluation and Research for the second time in under a year, major deal activity including a GSK and Alfasigma licensing agreement along with Servier’s $2 billion acquisition of Day One Pharmaceuticals, and Ipsen withdraws Tazverik from the market following emerging clinical trial data.